nitrogen mustard

(redirected from Mechlorethamine)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Mechlorethamine: procarbazine, Mechlorethamine hydrochloride, Mustargen

nitrogen mustard,

any of various poisonous compounds originally developed for military use (see poison gaspoison gas,
any of various gases sometimes used in warfare or riot control because of their poisonous or corrosive nature. These gases may be roughly grouped according to the portal of entry into the body and their physiological effects.
..... Click the link for more information.
). Like mustard gas and lewisite, it is a vesicant (blistering agent). In the form of its crystalline hydrochloride it is used as a drug in the treatment of Hodgkin's diseaseHodgkin's disease,
a type of cancer of the lymphatic system. First identified in 1832 in England by Thomas Hodgkin, it is a type of malignant lymphoma. Incidence peaks in young adults and the elderly.
..... Click the link for more information.
, non-Hodgkin's lymphomaslymphoma, non-Hodgkin's,
any cancer of the lymphoid tissue (see lymphatic system) in which the Reed-Sternberg cells characteristic of Hodgkin's disease (the other category of lymphoma) are not present.
..... Click the link for more information.
, and brain tumors. Nitrogen mustards cause mutations in the genetic material of cells, thereby disrupting mitosis, or cell division. Cells vary in their susceptibility to nitrogen mustards, with rapidly proliferating tumor and cancer cells most sensitive; bone marrow, which produces red blood cells, is also sensitive, and depression of red blood cell production is a frequent side effect of nitrogen mustard therapy. The nitrogen mustards also suppress the immune response (see immunityimmunity,
ability of an organism to resist disease by identifying and destroying foreign substances or organisms. Although all animals have some immune capabilities, little is known about nonmammalian immunity.
..... Click the link for more information.
).

nitrogen mustard

[′nī·trə·jən ′məs·tərd]
(organic chemistry)
Any of the substituted mustard gases in which the sulfur is replaced by an amino nitrogen, such as for methyl bis(2-chlorethyl)amine, (CH2ClCH2)2NCH3; useful in cancer research.
References in periodicals archive ?
Prior to the financing, Ceptaris received a Complete Response Letter from the Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
The funding will be used for ongoing operational expenses and preparation for commercialization of its investigational drug, mechlorethamine gel.
The EMA's decision to grant Orphan Drug Designation to our proprietary mechlorethamine gel underscores the need for additional therapeutic alternatives for patients with Cutaneous T-Cell Lymphoma," said Ceptaris Chairman of the Board and CEO Steve Tullman.
In recent years, many patients and caregivers have had their medical care complicated by drug shortages, primarily of generic injectable drugs like mechlorethamine.
The new drug application (NDA) for Ceptaris' mechlorethamine gel was filed in July 2011.
Currently, topical mechlorethamine preparations are recommended for treatment of early stage CTCL by the National Comprehensive Cancer Network (NCCN).
Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).
New management to focus on NDA submission for proprietary gel formulation of mechlorethamine hydrochloride to treat early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma -
Yaupon to focus on submission of NDA for proprietary mechlorethamine gel for early stage Cutaneous T-Cell Lymphoma (CTCL) based on positive pivotal study data
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa).